Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
SPRO
$2.23
$
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Next Earnings
2026-02-25
Beta
1.451
Average Volume
Market Cap
Last Dividend
CIK
0001701108
ISIN
US84833T1034
CUSIP
84833T103
CEO
Esther Rajavelu
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
32
IPO Date
2017-11-02
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Spero Therapeutics: Tebipenem's FDA Path Supports A Speculative Buy | Spero Therapeutics' lead asset is an oral carbapenem tebipenem for cUTI. This asset achieved Phase 3 noninferiority. In fact, this data supports GSK's NDA resubmission strategy. The prior FDA setback from ADAPT-PO was addressed through PIVOT-PO. The new PIVOT-PO trial was actually stopped early after strong interim efficacy results. So, I believe their data is quite favorable this time. | Seeking Alpha | 2026-02-11 08:43:11 |
| Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200 Day Moving Average – What’s Next? | Shares of Spero Therapeutics, Inc. (NASDAQ: SPRO - Get Free Report) crossed below its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $2.24 and traded as low as $2.19. Spero Therapeutics shares last traded at $2.29, with a volume of 937,759 shares traded. Wall | Defense World | 2026-02-05 04:33:04 |
| Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis | CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that its development partner, GSK, filed a New Drug Application (NDA) resubmission to the U.S. Food and Drug Administration (FDA) for tebipenem HBr, an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis. | GlobeNewsWire | 2025-12-19 08:00:00 |
| Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Nov. 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on November 3, 2025, the Compensation Committee of Spero's Board of Directors approved the grant of an aggregate of 90,000 restricted stock unit awards (RSUs) to one new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The RSUs are being granted as an inducement material to Spero's new employee in accordance with Nasdaq Listing Rule 5635(c)(4). | GlobeNewsWire | 2025-11-28 08:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-02-09 | 2026-02-09 | View Filing |
| 4 | 2026-02-09 | 2026-02-09 | View Filing |
| 4 | 2026-02-05 | 2026-02-05 | View Filing |
| 4 | 2026-02-04 | 2026-02-04 | View Filing |
| 8-K | 2026-01-30 | 2026-01-30 | View Filing |
| 8-K | 2025-12-19 | 2025-12-19 | View Filing |
| 8-K | 2025-11-13 | 2025-11-13 | View Filing |
| 10-Q | 2025-11-13 | 2025-11-13 | View Filing |
| 4 | 2025-11-12 | 2025-11-12 | View Filing |
| 4 | 2025-09-03 | 2025-09-03 | View Filing |
| 4 | 2025-09-03 | 2025-09-03 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| S-8 | 2025-08-12 | 2025-08-12 | View Filing |
| 10-Q | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-06-18 | 2025-06-18 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 8-K | 2025-05-28 | 2025-05-28 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| 10-Q | 2025-05-13 | 2025-05-13 | View Filing |
| 4 | 2025-05-06 | 2025-05-06 | View Filing |
| ARS | 2025-04-28 | 2025-04-28 | View Filing |
| DEFA14A | 2025-04-28 | 2025-04-28 | View Filing |
| DEF 14A | 2025-04-28 | 2025-04-28 | View Filing |
| 8-K | 2025-04-28 | 2025-04-28 | View Filing |
| SC 13D/A | 2025-03-28 | 2025-03-28 | View Filing |
| 8-K | 2025-03-27 | 2025-03-27 | View Filing |
| 10-K | 2025-03-27 | 2025-03-27 | View Filing |
| 8-K | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-05 | 2025-02-05 | View Filing |
| 4 | 2025-02-05 | 2025-02-05 | View Filing |
| 4 | 2025-02-05 | 2025-02-05 | View Filing |
| 4 | 2025-02-05 | 2025-02-05 | View Filing |
| 8-K | 2025-01-10 | 2025-01-10 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| 8-K | 2024-11-14 | 2024-11-14 | View Filing |
| 10-Q | 2024-11-14 | 2024-11-14 | View Filing |
| 4 | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-10-29 | 2024-10-29 | View Filing |
| 8-K | 2024-09-10 | 2024-09-10 | View Filing |
| 4 | 2024-08-29 | 2024-08-29 | View Filing |
| 4 | 2024-08-29 | 2024-08-29 | View Filing |
| 4 | 2024-08-29 | 2024-08-29 | View Filing |
| 4 | 2024-08-06 | 2024-08-06 | View Filing |
| S-8 | 2024-08-05 | 2024-08-05 | View Filing |
| 10-Q | 2024-08-05 | 2024-08-05 | View Filing |
| 8-K | 2024-08-05 | 2024-08-05 | View Filing |
| 8-K | 2024-06-03 | 2024-06-03 | View Filing |
| 4 | 2024-05-30 | 2024-05-30 | View Filing |
| 4 | 2024-05-30 | 2024-05-30 | View Filing |
| 4 | 2024-05-30 | 2024-05-30 | View Filing |
| 4 | 2024-05-30 | 2024-05-30 | View Filing |
| 4 | 2024-05-30 | 2024-05-30 | View Filing |
| 4 | 2024-05-30 | 2024-05-30 | View Filing |
| 4 | 2024-05-30 | 2024-05-30 | View Filing |
| 4 | 2024-05-30 | 2024-05-30 | View Filing |
| 8-K | 2024-05-15 | 2024-05-15 | View Filing |
| 10-Q | 2024-05-15 | 2024-05-15 | View Filing |
| ARS | 2024-04-16 | 2024-04-16 | View Filing |
| DEFA14A | 2024-04-16 | 2024-04-16 | View Filing |
| DEF 14A | 2024-04-16 | 2024-04-16 | View Filing |
| 8-K | 2024-03-29 | 2024-03-29 | View Filing |
| EFFECT | 2024-03-25 | 2024-03-25 | View Filing |
| S-3 | 2024-03-15 | 2024-03-15 | View Filing |
| S-8 | 2024-03-15 | 2024-03-15 | View Filing |
| 10-K | 2024-03-13 | 2024-03-13 | View Filing |
| 8-K | 2024-03-13 | 2024-03-13 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Neural Forcast | 13.94% | 1.19 | 20 | 0.93 | 67.02 | 11.27 |
| Quantum Inspired Strategy | 12.38% | 1.13 | 19 | 0.7 | 0.35 | 9.71 |
| Bull Bias | 9.70% | 1.07 | 39 | 0.35 | 0.24 | 7.03 |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | x | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxx | xxxxx% | x | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxx |
| xxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxxx | xxxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | x | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |